raluridine
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Nov 2, 1999 (NCT00002338)
Timeline
1990s
- Jan 1, 1999
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Histamine H2 receptorINHIBITOR
HRH2 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
O=c1[nH]c(=O)n([C@H]2C[C@H](F)[C@@H](CO)O2)cc1Cl- Mol. weight
- 264.64 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2106991 ↗
Also known as
- 3'-fluoro-2',3'-dideoxy-5-chlorouridine
- 5-chloro-2',3'-dideoxy-3'-fluorouridine
- 935u83
- 935u83
- 935u83
- fddclurd
- raluridine
- raluridine
- raluridine
- raluridine
- raluridine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00002338 | Phase 1 | Nov 2, 1999 | Glaxo Wellcome |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Glaxo Wellcome | For profit | 1 | 1 | 1 | 1999 |
1 organizations
Page 1 / 1